Clinical Trials

Study is being done to see if we can possibly shrink or prevent your head and neck cancer from spreading by adding an antibody drug (cetuximab) to your immunotherapy treatment (pembrolizumab).

The purpose of the GORE CARDIOFORM Septal Occluder (GSO Device) post-approval study is to assess the safety and effectiveness of GSO device as observed in the REDUCE pivotal IDE study, and to evaluate the quality of the operator education and training and transferability of trial experience to a post-market setting.

The purpose of this study is to compare a usual treatment alone to using MEDI4736 (durvalumab) plus the usual treatment. The study approach could shrink your cancer. But, it could also cause side effects, which are described in the risks section below. MEDI4736 (durvalumab) is a type of immunotherapy drug that is already approved by the FDA for use in urothelial cancer. But, most of the time it is not used until platinum-containing chemotherapy, such as cisplatin, stops working for your cancer. This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking at two main factors. They will be investigating if the study approach will increase the number of patients whose cancer is shrunk significantly after surgery. They will also be investigating if the study approach increases the number of patients who do not have the cancer come back or get worse.

Demonstrate the effectiveness of LAA exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for artial fibrillation and ischemic stroke

This study is for advanced cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists.

This a phase II clinical trial for patients with advanced papillary kidney cancer (renal cell carcinoma), which compares the use of cabozantinib alone versus cabozantinib in combination with atezolizumab.

This is study is treating low tumor burden follicular lymphoma, a type of slow-growing (indolent) blood cancer with a minimal amount of disease present in the body. The purpose of this study is to compare the usual treatment (rituximab) to using the study drug mosunetuzumab.

This study wants to find out if a blood test can help doctors decide which patients need more treatment after surgical removal of the bladder, kidney, ureter, or urethra. This blood test looks for small pieces of cancer DNA, called ctDNA, in the blood. If ctDNA is found, it means some cancer cells may still be in the body. The trial will give some patients an extra medicine, called immunotherapy, to help their immune system find and kill any remaining cancer. This will help doctors learn if using the blood test to guide treatment will help patients live longer without their cancer coming back.

This study tests treatment for people with early-stage breast cancer that has a high chance of coming back after treatment. It will test adding an immunotherapy drug called durvalumab to usual chemotherapy before surgery. To determine if cancer has a high chance of returning, the trial uses a test called MammaPrint. The MammaPrint test predicts how likely it is the cancer will come back (recur) by looking at many genes in cancer cells. Treatment in the trial is for patients who receive a High 2 result on MammaPrint testing.

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.